USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: G1 THERAPEUTICS, INC.
Address: 450 WEST DR, CB 7295
CHAPEL HILL, NC
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,003,277.00 3
SBIR Phase II $3,000,000.00 1

Award List:

Organismal Radioprotection Through Pharmacological Quiescence

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: John S. Chant
Award Amount: $692,326.00
Abstract:
DESCRIPTION (provided by applicant): Hematologic toxicity is a principal cause of morbidity and mortality after exposure to ionizing radiation (IR). G-Zero Therapeutics, with operations in the Research Triangle Park, North Carolina, has developed a nov el approach to mitigating the hematologic… More

Organismal Radioprotection Through Pharmacological Quiescence

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Jay C. Strum – 919-966-9755
Award Amount: $3,000,000.00
Abstract:
DESCRIPTION (provided by applicant): Syndrome (ARS), including a lethal myelosuppression due to the sensitivity of proliferating hematopoietic stem/progenitor cells (HSPCs) to ionizing radiation (IR). No effective therapy exists to mitigate the hematologictoxicities of TBI. Herein G-Zero… More

Development of CDK4/6 Inhibitors as Novel Renal Protectants

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jay C. Strum – 919-966-9755
Award Amount: $159,836.00
Abstract:
DESCRIPTION (provided by applicant): Acute kidney injury (AKI) is common, expensive, and highly morbid. There are currently no therapies for AKI, and prevention and treatment represents a 6.3 billion market opportunity annually in the U.S. Moreover, patients are developing AKI more frequently and… More

A new multiphase polymeric material for cushion-bearing orthopedic implants

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jay C. Strum – 919-966-9755
Award Amount: $151,115.00
Abstract:
DESCRIPTION (provided by applicant): Myelosuppression continues to represent the major dose-limiting toxicity of cancer chemotherapy, resulting in considerable morbidity and mortality along with frequent reductions in chemotherapy dose intensity, which maycompromise disease control and survival.… More